Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 22;17:11795549231199915. doi: 10.1177/11795549231199915

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 7. — SPAG5 may be a predictor of response to LUAD immunotherapy. (A and B) Based on the H-score evaluation of SPAG5 expression levels through IHC staining, a chi-square test was conducted to analyze the differential rates of PD-L1 positivity among LUAD samples with high and low SPAG5 expression. PD-L1 positivity was assessed using IHC staining with SP142 and SP263 antibodies in panels A and B, respectively. (C) Analysis of the LUAD sequencing data of TCGA by ImmuCellAI website showed that the expression of SPAG5 is positively correlated with good ICB therapy response. ICB indicates checkpoint blockade; IHC, immunohistochemistry; LUAD, lung adenocarcinoma; Mφ, macrophages; PD-L1, programmed death-ligand 1; SPAG5, sperm-associated antigen 5; TCGA, The Cancer Genome Atlas.